Transplacental carcinogenicity of inorganic arsenic in the drinking water: Induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice

Toxicology and Applied Pharmacology

Volumn 186, Issue 1, 2003, Pages 7-17

  Waalkes, Michael P ^a   Ward, Jerrold M ^b   Liu, Jie ^a   Diwan, Bhalchandra A ^c  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Animal Models; Arsenic; Carcinogenesis; Mice; Transplacental

Indexed keywords

ARSENIC; ARSENITE SODIUM; DRINKING WATER;

ADRENAL CANCER; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BIRTH; BODY WEIGHT; CANCER INCIDENCE; CARCINOGENICITY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MICROSCOPY; MOUSE; NONHUMAN; OVARY CANCER; PREGNANCY; TRANSPLACENTAL CARCINOGENESIS; WEANING;

ANIMALIA; RODENTIA;

EID: 0037284858     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-008X(02)00022-4     Document Type: Article

References (43)

1. Aldick H.J., Fabry H. Multiple basaliome durch arseneinwirkung in der fetalperiode. Der Hautarzt. 24:1973;496.
2. Aposhian H.V. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol. 37:1997;397-419.
3. Basu A., Mahata J., Gupta S., Giri A.K. Genetic toxicology of a paradoxical human carcinogen, arsenic a review . Mutat. Res. 448:2001;171-194.
4. Bates M.N., Smith A.H., Hopenhayn-Rich C. Arsenic ingestion and internal cancers a review . Am. J. Epidemiol. 135:1992;462-476.
5. Chen C.-J., Wang C.-J. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res. 50:1990;5470-5474.
6. Concha G., Vogler G., Lezcano D., Nermell B., Vahter M. Exposure to inorganic arsenic metabolites during early human development. Toxicol. Sci. 44:1998;185-190.
7. Del Razo L.M., Quintanilla-Vega B., Brambila-Colombres E., Calderon-Aranda E., Manno M., Albores A. Stress proteins induced by arsenic. Toxicol. Appl. Pharmacol. 177:2001;132-148.
8. Diwan B.A., Anderson L.M., Rehm S., Rice J.M. Transplacental carcinogenicity of cisplatin initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice . Cancer Res. 53:1993;3874-3876.
9. Diwan B.A., Anderson L.M., Ward J.M., Henneman J.R., Rice J.M. Transplacental carcinogenesis by cisplatin in F344/NCr Promotion of kidney tumors by postnatal administration of sodium barbital . Toxicol. Appl. Pharmacol. 132:1995;115-121.
10. Diwan B.A., Kasprzak K.S., Rice J.M. Transplacental carcinogenic effects of nickel(II) in the renal cortex, renal pelvis and adenohypophysis in F344/NCr. Carcinogenesis. 13:1992;1351-1357.
11. Germolec D.R., Spalding J., Boorman G.A., Wilmer J.L., Yoshida T., Simeonova P.P., Bruccoleri A., Kayama F., Gaido K., Tennant R., Burleson F., Dong W., Lang R.W., Luster M.I. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat. Res. 386:1997;209-218.
12. Germolec D.R., Spalding J., Yu H.-S., Chen G.S., Simeonova P.P., Humble M.C., Bruccoleri A., Boorman G.A., Foley J.F., Yoshida T., Luster M.I. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153:1998;1775-1785.
13. Goodman J.I. Operational reversibility is a key aspect of carcinogenesis. Toxicol. Sci. 64:2001;147-148.
14. Guha-Muzumder D.N., Haque R., Ghosh N., De B.K., Santra A., Chakroborty D., Smith A.H. Arsenic levels in the drinking water and the prevalence of skin lesions in West Bengal, India. Int. J. Epidemiol. 27:1998;871-877.
15. Hughes M.F., Kenyon E.M., Edwards B.C., Mitchell C.T., Thomas D.J. Strain-dependent disposition of inorganic arsenic in the mouse. Toxicology. 137:1999;95-108.
16. IARC, 1987. International agency for research on cancer monographs on the evaluation of carcinogenic risks to humans: supplement 7, overall evaluations of carcinogenicity: an updating of IARC monographs Volumes 1 to 42, IARC Scientific Publications, Lyon, France, pp. 100-106.
17. Kenyon E., Hughes M.F. A concise review of the toxicity and carcinogenicity of dimethylarsinic acid. Toxicology. 160:2001;227-236.
18. Kitchin K.T. Recent advances in arsenic carcinogenesis modes of action, animal model systems, and methylated arsenic metabolites . Toxicol. Appl. Pharmacol. 172:2001;249-261.
19. Lewis D.R., Southwick J.W., Ouellet-Hellstrom R., Rench J., Calderon R.L. Drinking water arsenic in Utah a cohort mortality study . Environ. Health Perspect. 107:1999;359-365.
20. Lindgren A., Danielsson R.G., Dencker L., Vathter M. Embryotoxicity of arsenite and arsenate distribution in pregnant mice and monkeys and effects on embryonic cells in vitro . Acta Pharmacol. Toxicol. 54:1984;311-320.
21. Mass M.J., Tennant A., Roop B.C., Cullen W.R., Styblo M., Thomas D.J., Kligerman A.D. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol. 14:2001;355-361.
22. Morales K.H., Ryan L., Kuo T.-L., Wu M.-M., Chen C.-J. Risk of internal cancers from arsenic in the drinking water. Environ. Health Perspect. 108:2000;655-661.
23. Morikawa T., Wanibuchi H., Morimura K., Ogawa M., Fukushima S. Promotion of skin carcinogenesis by dimethylarsinic acid in Keratin (K6)/ODC transgenic mice. Jpn. J. Cancer Res. 91:2000;579-581.
24. Arsenic in the Drinking Water. 1999;1-310 National Academy Press, Washington, DC.
25. III) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163, 203-207.
26. Pitot H.C., Dragan Y.P. Chemical carcinogenesis. Klaassen C.D. Toxicology The Basic Science of Poisons . 1996;199-200 McGraw-Hill, New York.
27. Pott W.A., Bengamin S.A., Yang R.S.H. Pharmacokinetics, metabolism and carcinogenicity of arsenic. Rev. Environ. Contam. Toxicol. 169:2001;165-214.
28. Rossman T.G., Uddin A.N., Burns F.J., Bosland M.C. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin an animal model for arsenic carcinogenesis . Toxicol. Appl. Pharmacol. 176:2001;64-71.
29. Simeonova P.P., Luster M.I. Mechanisms of arsenic carcinogencity genetic or epigenetic mechanisms? J. Environ. Pathol. Oncol. 19:2000;281-286.
30. Smith A.H., Hopenhayn-Rich C., Bates M.N., Goeden H.M., Hertz-Picciotto I., Duggan H.M., Wood R., Kosnett M.J., Smith M.T. Cancer risks from arsenic in drinking water. Environ. Health Perspect. 97:1992;259-267.
31. Styblo M., Del Razo L.M., Vega L., Germolic D.R., LeCluyse E.L., Hamilton G.A., Wang C., Cullen W.R., Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in human cells. Arch. Toxicol. 74:2000;289-299.
32. Thomas D.J., Styblo M., Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 176:2001;127-144.
33. Tsai S.-M., Wang T.-N., Ko Y.-C. Mortality for certain disease in areas with high levels of arsenic in drinking water. Arch. Environ. Health. 54:1999;186-193.
34. 1 mice exposed to lead acetate during gestation and lactation occur with minimal chronic nephropathy. Cancer Res. 55:1995;5265-5271.
35. Waalkes M.P., Keefer L.K., Diwan B.A. Induction of proliferative lesions of the uterus, testes, and liver in Swiss mice given repeated injections of sodium arsenate possible estrogenic mode of action . Toxicol. Appl. Pharmacol. 166:2000;24-35.
36. Warner M.L., Moore L.E., Smith M.T., Kalman D.A., Fanning D.A., Smith A.H. Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol. Biomarkers Prevent. 3:1994;583-590.
37. Wei M., Wanibuchi H., Salim E.I., Yamamoto S., Yoshida K., Endo G., Fukushima S. Promotion of NCI-Black-Reiter male rat bladder carcinogenesis by dimethylarsinic acid an organic arsenic compound. Cancer Lett. 134:1998;29-36.
38. Wei M., Wanibuchi H., Yamamoto S., Li W., Fukushima S. Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis. 20:1999;1873-1876.
39. Williams G.M., Iatropoulos M.J. Principles of testing for carcinogenic activity. Hayes A.W. Principles and Methods of Toxicology. 2001;959-1000 Taylor and Francis, Philadelphia.
40. Wu M.-M., Kuo T.-L., Hwang Y.-H., Chen C.-J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am. J. Epidemiol. 130:1989;1123-1132.
41. Yamamoto S., Konishi Y., Matsuda T., Murai T., Shibata M.-A., Matsui-Yuasa I., Otani S., Kuroda K., Endo G., Fukushima S. Cancer induction by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res. 55:1995;1271-1276.
42. Yamanaka K., Katsumata K., Ikuma K., Hasegawa A., Nakano M., Okada S. The role of orally administered dimethylarsinic acid, a main metabolite of inorganic arsenics, in the promotion and progression of UVB-induced skin tumorigenesis in hairless mice. Cancer Lett. 152:2000;79-85.
43. Zhao C.Q., Young M.R., Diwan B.A., Coogan T.P., Waalkes M.P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. USA. 94:1997;10907-10912.